Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0BL2G)

Drug Name
Mitiperstat Drug Info
Synonyms
Mitiperstat; AZD4831; Mitiperstat [INN]; AZD-4831; S6GYK3X4QQ; 1933460-19-5; UNII-S6GYK3X4QQ; AZD-4831 [WHO-DD]; 1-((2-((1R)-1-Aminoethyl)-4-chloro-phenyl)methyl)-2-thioxo-5hpyrrolo(3,2-d)pyrimidin-4-one; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 1-((2-((1R)-1-aminoethyl)-4-chlorophenyl)methyl)-1,2,3,5-tetrahydro-2-thioxo-; 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-1,2,3,5-tetrahydro-2-thioxo-; Alternative Preparation; MITIPERSTAT [USAN]; Azd 4831; CHEMBL5095218; SCHEMBL17782047; GTPL12154; AZD 4831 [WHO-DD]; BHKKSKOHRFHHIN-MRVPVSSYSA-N; BDBM312172; GLXC-26157; EX-A7129; compound 16 [PMID: 36005476]; HY-145581; CS-0376445; US9616063, 3; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1H,2H,3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-{2-[(1R)-1-Aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
Indication
Disease Entry ICD 11 Status REF
Heart failure with preserved ejection fraction BD11.0 Phase 2/3 [1]
Chronic obstructive pulmonary disease CA22 Phase 2 [2]
Cross-matching ID
PubChem CID
121362450
TTD Drug ID
DM0BL2G

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloperoxidase (MPO) TTVCZPI PERM_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Myeloperoxidase (MPO) DTT MPO 5.085 4.154 4.066 5.007
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Heart failure with preserved ejection fraction
ICD Disease Classification BD11.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myeloperoxidase (MPO) DTT MPO 2.88E-01 -0.02 -0.16
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04986202) A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05492877) A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
3 Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65(17):11485-11496.